Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer

Journal of Lipid Research

Volumn 47, Issue 2, 2006, Pages 349-355

  Purnell, Jonathan Q ^a,b   Bland, Lisa B ^c   Garzotto, Mark ^c   Lemmon, Dianne ^c   Wersinger, Emily M ^c   Ryan, Christopher W ^c   Brunzell, John D ^d   Beer, Tomasz M ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen deprivation therapy; Apolipoprotein; Estradiol; Inflammation

Indexed keywords

ANDROGEN; ANTIANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESTROGEN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MALE; MORTALITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TIME SERIES ANALYSIS;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS B; BODY COMPOSITION; C-REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; ESTROGENS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEPTIN; LIPASE; LIPID METABOLISM; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33244469248     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M500276-JLR200     Document Type: Article

References (55)

1. Huggins, C., and C. V. Hodges. 1941. Studies in prostatic cancer. I. The effect of castration on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293-297.
2. Bolla, M., D. Gonzalez, P. Warde, J. B. Dubois, R. O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, T. Gil, et al. 1997. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337: 295-300.
3. Messing, E. M., J. Manola, M. Sarosdy, G. Wilding, E. D. Crawford, and D. Trump. 1999. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341: 1781-1788.
4. Pilepich, M. V., K. Winter, M. J. John, J. B. Mesic, W. Sause, P. Rubin, C. Lawton, M. Machtay, and D. Grignon. 2001. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50: 1243-1252.
5. Cooperberg, M. R., G. D. Grossfeld, D. P. Lubeck, and P. R. Carroll. 2003. National practice patterns and time trends in androgen ablation for localized prostate cancer. J. Natl. Cancer Inst. 95: 981-989.
6. Higano, C. S. 2003. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 61: 32-38.
7. Daniell, H. W., S. R. Dunn, D. W. Ferguson, G. Lomas, Z. Niazi, and P. T. Stratte. 2000. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. 163: 181-186.
8. Berruti, A., L. Dogliotti, C. Terrone, S. Cerutti, G. Isaia, R. Tarabuzzi, G. Reimondo, M. Mari, P. Ardissone, S. De Luca, et al. 2002. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 167: 2361-2367.
9. Smith, J. C., S. Bennett, L. M. Evans, H. G. Kynaston, M. Parmar, M. D. Mason, J. R. Cockcroft, M. F. Scanlon, and J. S. Davies. 2001. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86: 4261-4267.
10. Smith, M. R., J. S. Finkelstein, F. J. McGovern, A. L. Zietman, M. A. Fallon, D. A. Schoenfeld, and P. W. Kantoff. 2002. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87: 599-603.
11. Alexandersen, P., J. Haarbo, and C. Christiansen. 1996. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 125: 1-13.
12. Fukui, M., Y. Kitagawa, N. Nakamura, M. Kadono, S. Mogami, C. Hirata, N. Ichio, K. Wada, G. Hasegawa, and T. Yoshikawa. 2003. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 26: 1869-1873.
13. Lu-Yao, G., T. A. Stukel, and S. L. Yao. 2004. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J. Urol. 171: 2285-2290.
14. Moorjani, S., A. Dupont, F. Labrie, P. J. Lupien, D. Brun, C. Gagne, M. Giguere, and A. Belanger. 1987. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36: 244-250.
15. Xu, T., X. Wang, S. Hou, J. Zhu, X. Zhang, and X. Huang. 2002. Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin. Med. J. (Engl.). 115: 1336-1340.
16. Wallentin, L., and E. Varenhorst. 1981. Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma. Horm. Metab. Res. 13: 293-297.
17. Agardh, C. D., P. Nilsson-Ehle, R. Lundgren, and A. Gustafson. 1984. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma. J. Urol. 132: 1021-1024.
18. Bulusu, N. V., S. B. Lewis, S. Das, and W. E. Clayton, Jr. 1982. Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology. 20: 147-150.
19. Seal, U. S., R. P. Doe, D. P. Byar, and D. K. Corle. 1976. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer. 38: 1095-1107.
20. The Coronary Drug Project Research Group. 1973. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. J. Am. Med. Assoc. 226: 652-657.
21. de Voogt, H. J., P. H. Smith, M. Pavone-Macaluso, M. de Pauw, and S. Suciu. 1986. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J. Urol. 135: 303-307.
22. Grady, D., N. K. Wenger, D. Herrington, S. Khan, C. Furberg, D. Hunninghake, E. Vittinghoff, and S. Hulley. 2000. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. 132: 689-696.
23. Manson, J. E., J. Hsia, K. C. Johnson, J. E. Rossouw, A. R. Assaf, N. L. Lasser, M. Trevisan, H. R. Black, S. R. Heckbert, R. Detrano, et al. 2003. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349: 523-534.
24. Lucidi, P., G. Murdolo, C. Di Loreto, N. Parlanti, A. De Cicco, A. Ranchelli, C. Fatone, C. Taglioni, C. Fanelli, F. Santeusanio, et al. 2004. Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. J. Endocrinol. Invest. 27: RC12-RC15.
25. Henriksson, P., M. Blomback, A. Eriksson, R. Stege, and K. Carlstrom. 1990. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br. J. Urol. 65: 282-285.
26. Ockrim, J. L., E. N. Lalani, M. E. Laniado, S. S. Carter, and P. D. Abel. 2003. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J. Urol. 169: 1735-1737.
27. Bland, L. B., M. Garzotto, T. G. DeLoughery, C. W. Ryan, K. G. Schuff, E. M. Wersinger, D. Lemmon, and T. M. Beer. 2005. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 103: 717-723.
28. Warnick, G. R. 1986. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129: 101-123.
29. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density- lipoprotein cholesterol. Clin. Chem. 28: 1379-1388.
30. Warnick, G. R. (1994) Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. In Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins. N. Rifai and G. R. Warnick, editors. AACC Press, Washington, D.C. 207-222.
31. Marcovina, S. M., J. J. Albers, H. Kennedy, J. V. Mei, L. O. Henderson, and W. H. Hannon. 1994. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin. Chem. 40: 586-592.
32. Auwerx, J. H., C. A. Marzetta, J. E. Hokanson, and J. D. Brunzell. 1989. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 9: 319-325.
33. Iverius, P. H., and J. D. Brunzell. 1985. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am. J. Physiol. 249: E107-E114.
34. Vermeulen, A., L. Verdonck, and J. M. Kaufman. 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84: 3666-3672.
35. Bhasin, S. 2003. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin. Infect. Dis. 37 (Suppl. 2): 142-149.
36. Falahati-Nini, A., B. L. Riggs, E. J. Atkinson, W. M. O'Fallon, R. Eastell, and S. Khosla. 2000. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106: 1553-1560.
37. Bagatell, C. J., R. H. Knopp, J. E. Rivier, and W. J. Bremner. 1994. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J. Clin. Endocrinol. Metab. 78: 855-861.
38. Hedlund, P. O., M. Ala-Opas, E. Brekkan, J. E. Damber, L. Damber, I. Hagerman, S. Haukaas, P. Henriksson, P. Iversen, A. Pousette, et al. 2002. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) study no. 5. Scand. J. Urol. Nephrol. 36: 405-413.
39. Cushman, M., C. Legault, E. Barrett-Connor, M. L. Stefanick, C. Kessler, H. L. Judd, P. A. Sakkinen, and R. P. Tracy. 1999. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation. 100: 717-722.
40. Wakatsuki, A., N. Ikenoue, K. Shinohara, K. Watanabe, and T. Fukaya. 2004. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 24: 571-576.
41. Scarabin, P. Y., M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach. 1997. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17: 3071-3078.
42. Vehkavaara, S., A. Silveira, T. Hakala-Ala-Pietila, A. Virkamaki, O. Hovatta, A. Hamsten, M. R. Taskinen, and H. Yki-Jarvinen. 2001. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85: 619-625.
43. Lacut, K., E. Oger, G. Le Gal, M. T. Blouch, J. F. Abgrall, V. Kerlan, P. Y. Scarabin, and D. Mottier. 2003. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90: 124-131.
44. Kontturi, M., and E. Sotaniemi. 1971. Effect of estrogen on the serum cholesterol and triglyceride levels of prostatic cancer patients. J. Urol. 105: 847-849.
45. Shahmanesh, M., C. H. Bolton, R. C. Feneley, and M. Hartog. 1973. Metabolic effects of oestrogen treatment in patients with carcinoma of prostate: a comparison of stilboestrol and conjugated equine oestrogens. Br. Med. J. 2: 512-514.
46. Sotanieme, E. A., and M. J. Kontture. 1975. Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer. Scand. J. Urol. Nephrol. 9: 89-93.
47. Walsh, B. W., I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F. M. Sacks. 1991. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325: 1196-1204.
48. Carr, M. C., J. E. Hokanson, A. Zambon, S. S. Deeb, P. H. Barrett, J. Q. Purnell, and J. D. Brunzell. 2001. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J. Clin. Endocrinol. Metab. 86: 2831-2837.
49. Meschia, M., F. Bruschi, M. Soma, F. Amicarelli, R. Paoletti, and P. Crosignani. 1998. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause. 5: 157-162.
50. Zegura, B., I. Keber, M. Sebestjen, and W. Koenig. 2003. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis. 168: 123-129.
51. Stevenson, J. C., A. Oladipo, N. Manassiev, M. I. Whitehead, S. Guilford, and A. J. Proudler. 2004. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br. J. Haematol. 124: 802-808.
52. Saad, M. F., S. Damani, R. L. Gingerich, M. G. Riad-Gabriel, A. Khan, R. Boyadjian, S. D. Jinagouda, K. el-Tawil, R. K. Rude, and V. Kamdar. 1997. Sexual dimorphism in plasma leptin concentration. J. Clin. Endocrinol. Metab. 82: 579-584.
53. Elbers, J. M., H. Asscheman, J. C. Seidell, M. Frolich, A. E. Meinders, and L. J. Gooren. 1997. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J. Clin. Endocrinol. Metab. 82: 3267-3270.
54. Haffner, S. M., L. Mykkanen, and M. P. Stern. 1997. Leptin concentrations in women in the San Antonio Heart Study: effect of menopausal status and postmenopausal hormone replacement therapy. Am. J. Epidemiol. 146: 581-585.
55. Cagnacci, A., S. Malmusi, S. Arangino, A. Zanni, L. Rovati, P. Cagnacci, and A. Volpe. 2002. Influence of transdermal estradiol in the regulation of leptin levels of postmenopausal women: a double-blind, placebo-controlled study. Menopause. 9: 65-71.